Clinical Trials
GeoVax to Showcase Vaccine and Cancer Therapy Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA, GEO-CM04S1, and Gedeptin® programs at the Emerging Growth Conference, highlighting advancements in vaccine development and cancer therapy.
NanoViricides Advances MPox Treatment with Adaptive Clinical Trial Design
NanoViricides, Inc. nears finalization of an adaptive clinical trial protocol for NV-387, a potential first-in-class treatment for MPox, highlighting its significance amid limited effective therapies.
Fifty 1 Labs and UAV Corp Complete Historic REVIVE Trial, Pioneering Long COVID Treatment
Fifty 1 Labs, Inc. and UAV Corp have successfully completed the REVIVE Adaptive Platform Trial, marking a significant advancement in the treatment of Long COVID and positioning the companies for growth in the functional medicine market.
CNS Pharmaceuticals Inc. Showcases Lead Cancer Treatment Program in Virtual CEO Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) emphasizes its lead cancer treatment program during a virtual CEO segment, highlighting potential advancements in brain and central nervous system cancer therapies.
Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Potential $2 Billion Global Opportunity
Soligenix Inc. outlines significant clinical and strategic milestones for its rare disease therapies, including Phase 3 FLASH 2 results for HyBryte(TM) and updates on psoriasis and Behçet’s Disease treatments, projecting over $90 million in U.S. annual sales and global opportunities exceeding $2 billion.
Quantum BioPharma Submits MS Drug Candidate to UK's ILAP Program
Quantum BioPharma Ltd. advances its multiple sclerosis treatment, Lucid-MS, through the UK's Innovative Licensing and Access Pathway, aiming to accelerate patient access to this innovative therapy.
NeuroEyeCoach Study Highlights Benefits for Vision Rehabilitation in Home and Clinic Settings
A new study on NovaVision's NeuroEyeCoach demonstrates significant improvements in visual search performance for patients, whether used at home or in a clinic, supporting its role in vision rehabilitation.
Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha
A recent study presented at the 2025 Diabetic Limb Salvage Conference reveals the Benova Mouth Rinse System's ability to reduce TNF-alpha, a key inflammatory marker, by 17% within two minutes, offering potential relief for millions suffering from oral inflammatory conditions.
Clene Inc. Advances Neurofilament Biomarker Analysis for CNM-Au8 in ALS with FDA Support
Clene Inc. is set to conduct a neurofilament biomarker analysis for CNM-Au8 in ALS patients, following constructive FDA feedback, aiming to support an accelerated approval submission in 2025.
Soligenix Inc. Reports Promising Phase 3 Progress for HyBryte(TM) in CTCL Treatment
Soligenix Inc. shares encouraging interim results from its phase 3 trial of HyBryte(TM) for cutaneous T-cell lymphoma, highlighting potential advancements in treatment options for this rare disease.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
6th Clinical Trial Agreements Summit to Address Key Industry Challenges
The upcoming 6th Clinical Trial Agreements Summit in Philadelphia will tackle critical issues like budgetary negotiations, intellectual property protection, and risk reduction in clinical trials, featuring insights from over 30 industry experts.
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
Clene Inc. Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene Inc. progresses in its regulatory strategy for CNM-Au8, with FDA meetings set to discuss ALS and MS treatments, marking a significant step towards potential accelerated approval.
Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
SeaStar's QUELIMMUNE Shows Promise in Halving Pediatric Sepsis Mortality Rates
SeaStar Medical's QUELIMMUNE therapy, approved by the FDA in 2024, has demonstrated the potential to reduce pediatric sepsis mortality rates by half, offering hope for critically ill children with acute kidney injury.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
Annovis Bio Inc. will present significant advancements in Alzheimer’s treatment at the Alzheimer’s Association International Conference 2025, highlighting the potential of its lead candidate, buntanetap.
NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.
ABVC BioPharma CEO Recognized Among Influential Indian-Origin CEOs in Global Biotech
Dr. Uttam Patil, CEO of ABVC BioPharma, is highlighted for his leadership in advancing a novel botanical antidepressant, ABV-1504, which could revolutionize treatment for Major Depressive Disorder by eliminating suicidal ideation side effects.
Fermented Wheat Germ Could Enhance Immunotherapy Outcomes for Cancer Patients
A clinical trial at UC Davis is exploring the potential of fermented wheat germ to improve immunotherapy results for cancer patients, offering hope for better survival rates and quality of life.
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) explores the potential of its lead product candidate, TPI 287, in treating Glioblastoma Multiforme (GBM) and future metastatic tumor indications, as discussed by Dr. Erin Dunbar in a recent Virtual Investor KOL Connect segment.
FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy
The FDA's approval of Keytruda® for head and neck cancer treatment underscores the therapeutic potential of combining it with GeoVax’s Gedeptin®, aiming to enhance tumor clearance and reduce relapse rates.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
Soligenix's SGX302 Shows Promise in Psoriasis Treatment
Soligenix Inc.'s SGX302, a novel therapy for psoriasis, has demonstrated effectiveness and safety in Phase 2a trials, offering hope to millions affected by this autoimmune disorder.
Food Is Medicine Programs Show Promise in Improving Health Outcomes, More Research Needed
Recent findings highlight the potential of Food Is Medicine (FIM) programs to enhance diet quality and food security among individuals with chronic diseases, though further research is essential to understand their clinical impact fully.
Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.
PolyPid Secures $26.7 Million Funding, Advances Toward FDA Approval with Promising D-PLEX₁₀₀
PolyPid Ltd. has secured $26.7 million in funding following successful Phase 3 trial results for its surgical infection prevention technology, D-PLEX₁₀₀, positioning the company for FDA approval and significant market impact.